ARTICLE | Clinical News
AG-348: Phase II data
June 20, 2016 7:00 AM UTC
Top-line data from 18 transfusion-independent adult patients with pyruvate kinase deficiency in the open-label, international Phase II DRIVE-PK trial showed that twice-daily 50 and 300 mg oral AG-348 ...